Fig. 2

Achievement (A, B) and maintenance (C, D) of DAS28(CRP) remission (< 2.6) and LDA (≤ 3.2) (mNRI and AO)

Error bars represent 95% confidence intervals

^amFAS1: All patients within the FAS who completed 6 months of UPA 15 mg treatment and had DAS28(CRP) data available (n = 902) or who discontinued treatment for any reason before month 6 (n = 172). ^bNumber of patients in mFAS1 with non-missing data. ^cmFAS2: All patients within mFAS1 who achieved remission at 6 months and completed 12 months of UPA 15 mg treatment and had DAS28(CRP) data available (n = 317), or who discontinued treatment for any reason between 6 and 12 months (n = 23). ^dNumber of patients in mFAS2 with non-missing data. ^eAll patients within mFAS1 who achieved LDA at 6 months and completed 12 months of UPA 15 mg treatment and had DAS28(CRP) data available (n = 395), or who discontinued the study between 6 and 12 months (n = 41). ^fNumber of patients within mFAS1 who achieved LDA at 6 months and completed 12 months of UPA 15 mg treatment and had DAS28(CRP) data available, or who discontinued the study between 6 and 12 months with non-missing data

AO as observed, DAS28(CRP) disease activity score in 28 joints using C-reactive protein, FAS full analysis set, LDA low disease activity, mFAS modified FAS, mNRI modified non-responder imputation, RA rheumatoid arthritis, UPA upadacitinib